Role of EphA2 in the pathogenesis and treatment of gastric cancer

doi:10.3877/cma.j.issn.1674-0785.2025.07.008

Abstract

Abstract:

Gastric cancer is one of the most common malignant tumors in the world, characterized by a high degree of malignancy and poor prognosis. In recent years, immunotargeted therapy for tumors has become a hot research topic, and more and more biological targets have been discovered. Erythropoietin-induced hepatocyte receptor A2 (EphA2) is a receptor tyrosine kinase involved in the proliferation, invasion, and metastasis of gastric cancer cells. This article reviews the role of EphA2 in the pathogenesis of gastric cancer and its therapeutic potential.

Key words: Gastric cancer, EphA2, Cancer

Yuesheng Liu, Yuhang Yuan, Yifeng Wu, Hufang Yuan. Role of EphA2 in the pathogenesis and treatment of gastric cancer[J]. Chinese Journal of Clinicians(Electronic Edition), 2025, 19(07): 532-535.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2025.07.008

https://zhlcyszz.cma-cmc.com.cn/EN/Y2025/V19/I07/532

References 33

1	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
2	Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5): 584-590.
3	Yoshida N, Doyama H, Yano T, et al. Early gastric cancer detection in high-risk patients: a multicentre randomised controlled trial on the effect of second-generation narrow band imaging[J]. Gut, 2021, 70(1): 67-75.
4	Eusebi LH, Telese A, Marasco G, et al. Gastric cancer prevention strategies: A global perspective[J]. J Gastroenterol Hepatol, 2020, 35(9): 1495-1502.
5	Wei C, Du X, Hu J, et al. Perioperative chemotherapy versus adjuvant chemotherapy in patients with resectable gastric cancer: A systematic review with meta-analysis[J]. Crit Rev Oncol Hematol, 2023, 31: 104082.
6	Xiao T, Xiao Y, Wang W, et al. Targeting EphA2 in cancer[J]. J Hematol Oncol, 2020, 13(1): 114.
7	Tomiyama E, Fujita K, Matsuzaki, et al. EphA2 on urinary extracellular vesicles as a novel biomarker for bladder cancer diagnosis and its effect on the invasiveness of bladder cancer [J]. Br J Cancer, 2022, 127, 1312-1323.
8	Kim J, Chang IY, You HJ. Interactions between EGFR and EphA2 promote tumorigenesis through the action of Ephexin1[J]. Cell Death Dis, 2022, 13(6): 528.
9	Harris ED, Sharpe JC, Strozen T, et al. The EphA2 receptor regulates invasiveness and drug sensitivity in canine and human osteosarcoma cells[J]. Cells, 2024, 13(14): 1201.
10	Zhou Y, Sakurai H. Emerging and diverse functions of the EphA2 noncanonical pathway in cancer progression[J]. Biol Pharm Bull, 2017, 40(10): 1616-1624.
11	Li Y, Hu Y, Zhan X, et al. Meta-analysis reveals Helicobacter pylori mutual exclusivity and reproducible gastric microbiome alterations during gastric carcinoma progression[J]. Gut Microbes, 2023, 15(1): 2197835.
12	Leite M, Marques MS, Melo J, et al. Helicobacter Pylori targets the EPHA2 Receptor tyrosine kinase in gastric cells modulating key cellular functions[J]. Cells, 2020, 9(2): 513.
13	Hirabayashi M, Georges D, Clifford GM, et al. Estimating the global burden of epstein-barr virus-associated gastric cancer: A systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2023, 21(4): 922-930.e21.
14	Fekadu S, Kanehiro Y, Kartika AV, et al. Gastric epithelial attachment of helicobacter pylori induces EphA2 and NMHC-IIA receptors for epstein-barr virus[J]. Cancer Sci, 2021, 112(11): 4799-4811.
15	Shi D, Liu W, Zhang X, et al. MiR-BART1-3p and BART18-5p inhibit cell migration, proliferation and activate autophagy in Epstein-Barr virus-associated gastric cancer by targeting erythropoietin-producing human hepatocellular 2[J]. Virus Genes, 2023, 59(5): 703-715.
16	Ren HY, Shen JX, Mao XM, et al. Correlation between tumor vasculogenic mimicry and poor prognosis of human digestive cancer patients: A systematic review and meta-analysis[J]. Pathol Oncol Res, 2019, 25(3): 849-858.
17	Kim HS, Won YJ, Shim JH, et al. Role of EphA2-PI3K signaling in vasculogenic mimicry induced by cancer-associated fibroblasts in gastric cancer cells[J]. Oncol Lett, 2019, 18(3): 3031-3038.
18	Kim HS, Won YJ, Shim JH, et al. Morphological characteristics of vasculogenic mimicry and its correlation with EphA2 expression in gastric adenocarcinoma[J]. Sci Rep, 2019, 9(1): 3414.
19	Hong HN, Won YJ, Shim JH, et al. Cancer-associated fibroblasts promote gastric tumorigenesis through EphA2 activation in a ligand-independent manner[J]. J Cancer Res Clin Oncol, 2018, 144(9): 1649-1663.
20	Zhou Y, Oki R, Tanaka A, et al. Cellular stress induces non-canonical activation of the receptor tyrosine kinase EphA2 through the p38-MK2-RSK signaling pathway[J]. J Biol Chem, 2023, 299(5): 104699.
21	Han J, Wang L, Lv H, et al. EphA2 inhibits SRA01/04 cells apoptosis by suppressing autophagy via activating PI3K/Akt/mTOR pathway[J]. Arch Biochem Biophys, 2021, 711: 109024.
22	Mao L, Yuan W, Cai K, et al. EphA2-YES1-ANXA2 pathway promotes gastric cancer progression and metastasis[J]. Oncogene, 2021, 40(20): 3610-3623.
23	Peng Q, Chen L, Wu W, et al. EPH receptor A2 governs a feedback loop that activates Wnt/β-catenin signaling in gastric cancer[J]. Cell Death Dis, 2018, 9(12): 1146.
24	Huang C, Yuan W, Lai C, et al. EphA2-to-YAP pathway drives gastric cancer growth and therapy resistance[J]. Int J Cancer, 2020, 146(7): 1937-1949.
25	Wang F, Zhang H, Cheng Z. EPHA2 promotes the invasion and migration of human tongue squamous cell carcinoma Cal-27 cells by enhancing AKT/mTOR signaling pathway[J]. Biomed Res Int, 2021, 2021: 4219690.
26	Wang DH, Zhang YJ, Zhang SB, et al. Geldanamycin mediates the apoptosis of gastric carcinoma cells through inhibition of EphA2 protein expression[J]. Oncol Rep, 2014, 32(6): 2429-2436.
27	Lee H, Lee J, Sohn I, et al. To excavate biomarkers predictive of the response for capecitabine plus RAD001 through nanostring-based multigene assay in advanced gastric cancer patients[J]. J Cancer, 2016, 7(15): 2173-2178.
28	Wen Q, Chen Z, Chen Z, et al. EphA2 affects the sensitivity of oxaliplatin by inducing EMT in oxaliplatin-resistant gastric cancer cells[J]. Oncotarget, 2017, 8(29): 47998-48011.
29	Chen Z, Liu Z, Gao J, et al. EPHA2/MAPK pathway confers acquired resistance of afatinib in gastric cancer ANN ONCOL[J]. ANN ONCOL, 2018, 29.
30	Lee PC, Chen ST, Kuo TC, et al. C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer[J]. Oncogene, 2020, 39(13): 2724-2740.
31	Huang J, He Y, Mcleod HL, et al. miR-302b inhibits tumorigenesis by targeting EphA2 via Wnt/ β-catenin/EMT signaling cascade in gastric cancer[J]. BMC Cancer, 2017, 17(1): 886.
32	Song B, Lin HX, Dong LL, et al. MicroRNA-338 inhibits proliferation, migration, and invasion of gastric cancer cells by the Wnt/β-catenin signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2018, 22(5): 1290-1296.
33	Li R, Hu Z, Wang Z, et al. miR-125a-5p promotes gastric cancer growth and invasion by regulating the Hippo pathway[J]. J Clin Lab Anal, 2021, 35(12): e24078.

[1]	Qingqiu Chen, Ling Zhong, Ting Zhang, kongyong Zhang, Yu Gui, Xiaowei Qi, Lin Ren. Mechanism of IGF2BP2/CCNB2 axis promoting the progression of triple negative breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2025, 19(05): 287-295.
[2]	Zhengyuan Yan, Heng Zhang, Nengqi Cao, Xingchao Fang, Damin Chen. Clinical observation on the efficacy and safety of single-port plus one laparoscopic radical resection for colorectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(06): 615-618.
[3]	Su Yan, Hao Liang, Tao Huang. Laparoscopic enlarged resection of right hemicolonic cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(06): 609-609.
[4]	Peijiang Sun, Shang Cui, Yongjun Yang, Chao Yan, Huaizhi Wang. Laparoscopic extended pancreaticoduodenectomy with superior mesenteric artery first approach combined with portal vein resection and reconstruction (en-bloc) [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(05): 487-487.
[5]	Ruifang Li, Mingshuai Wang, Nianzeng Xing. Advances in the application of circulating tumor cells in the diagnosis and prognosis of bladder cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(06): 705-713.
[6]	Chao Tian, Ruoxi Huang, Maolin Jiang, Chongwei Xie, Pengfei Diao, Suquan Zhong, Dong Chen, Hangtao Wang, Guiliu Chen, Yujian Chen, Guoliang Li. Risk factors and time distribution of pelvic lymph node metastasis after neoadjuvant chemotherapy in different subtypes of prostate cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(06): 727-735.
[7]	Weini Meng, Jingjing Guan, Min Liu, Xiaoxue Wang, Haifeng Wang. Nursing experience of multiple complications after robot-assisted laparoscopic radical prostatectomy [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(06): 765-771.
[8]	Bowen Hu, Yalan Hu, Hui Liang. Common methods and research advances in early screening for prostate cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(06): 800-808.
[9]	Jiamin Wang, Ping Liu. Multidisciplinary consultation on difficult cases in Guangdong Urological Association (Phase 27): primary bladder cancer after renal transplantation [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(06): 809-814.
[10]	Zicong Wang, Yongsheng Wu. Potential effects and research progress of ileostomy on the body of patients [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2025, 19(05): 571-576.
[11]	Zhan Gao, Shasha Tang, Heng Qin, Guansong Wang, Wen Zhang. Analysis of clinical characteristics and risk factors of chronic obstructive pulmonary disease combined with lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(05): 685-690.
[12]	Wentao Zheng, Jing Xiao, Bing Ouyang, Yi Wu, Kaiyou Liao, Chunlin Li. Efficacy analysis of domestic drug-carrying microspheres CalliSpheres for bronchial artery chemoembolization in the treatment of stage Ⅲ~Ⅳ non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(05): 691-696.
[13]	Yue Tang, Jialu Chen, Delong Qin, Zonglong Li, Zhaohui Tang, Zhiwei Quan. Discussion of core and difficult problems of laparoscopic liver resection for recurrent hepatocellular carcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(05): 667-672.
[14]	Yuhan Hou, Fujin Jiang, Sugui Wang. Progress in immunotherapy of bladder cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2025, 19(06): 471-475.
[15]	Mei Wang, Yong Zhao, Jian Zhang, Lina Zhang, Jianhua Ding, Yu Cao. Predictive value of perirenal fat area measured by CT for anastomotic complications after laparoscopic intersphincteric resection [J]. Chinese Journal of Clinicians(Electronic Edition), 2025, 19(05): 367-373.

Please choose a citation manager

Content to export